The search for top penny stocks to buy in April, or in any month, is certainly an intriguing one. There are thousands of small and micro-cap stocks to choose from. Investors can certainly go down some pretty intriguing rabbit holes in assessing these penny stocks. Some are obviously better than others. But most are unprofitable […]

[embedded content] Phil Orlando, chief equity market strategist at Federated Hermes, is looking at cash, Treasuries, and defensive equities as his firm sees negative GDP prints for the US in the third and fourth quarter. He speaks on “Bloomberg Surveillance.” Follow Bloomberg for business news & analysis, up-to-the-minute market data, features, profiles and more: http://www.bloomberg.comConnect

Markets are improving, with the benchmark S&P 500 index up 9% on the year so far. The technology-laden Nasdaq index has gained 17% year to date. With a recovery underway, now looks like an opportune time for investors to wade back into high-growth stocks, while also looking for companies with attractive valuations. There happen to be

While still in the green for 2023 (up 26% year-to-date), SoFi Technologies (NASDAQ:SOFI) shares have languished at or near current prices over the past few months. Many uncertainties have been a drag on returns for SOFI stock. But these multiple layers of near-term uncertainty work to your advantage if you are a growth investor with

[embedded content] Veteran emerging-markets investor Mark Mobius talks about the drop in Chinese stocks and what it means for investors. A selloff in Chinese equities is deepening as traders weigh a barrage of economic and geopolitical risks, with global funds accelerating their exodus. The co-founder of Mobius Capital Partners speaks with Tom Mackenzie and Francine Lacqua on “Bloomberg Markets: European

Personalized medicine stocks are hot right now. This form of medicine based on the particular genes, proteins, and other substances in a person’s body.  It promises to revolutionize healthcare making stocks in companies offering this form of medicine very intriguing.  The potential return on such shares is clearly high: Developing these treatments requires massive investments